Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myeloma
•
Hematology
How would you approach choosing a regimen for a patient with multiple myeloma refractory to daratumumab and lenalidomide, with severe neuropathy from bortezomib?
Related Questions
What are alternative myeloma therapies for patients who are unable to afford lenalidomide or oral cyclophosphamide due to gaps in prescription drug coverage?
How would you approach a patient with solitary plasmacytoma with an FLC ratio >100, but a negative bone marrow biopsy and negative PET-CT?
What post-auto maintenance therapy do you recommend for patients with high-risk multiple myeloma?
How do you modify Daratumumab-RVD relative to the protocols used in trials when used as a first-line agent to transplant-eligible patients with myeloma?
For otherwise transplant-eligible patients with myeloma, given developments of bispecifics and CAR-T, what is your age cutoff for consolidative autologous transplant?
How would you approach the treatment of an elderly patient with multiple myeloma and CALR+ myelofibrosis with elevated platelets?
How is monoclonal gammopathy of renal significance (MGRS) different from myeloma kidney?
What induction regimen do you choose for high risk newly diagnosed multiple myeloma in light of the recent high risk focused studies?
How do you approach post-transplant maintenance for patients with high-risk myeloma?
How do you utilize immunoglobulin testing to affect treatment decisions in patients with myeloma?
